Polyclonal antibody preparation that depletes and suppresses T lymphocytes to reduce autoimmune marrow destruction.
Polyclonal anti-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and depletes/suppresses T lymphocytes via complement-dependent cytolysis and Fc-mediated clearance, reducing autoreactive T‑cell–mediated marrow destruction.
ALG antibodies bind T‑cell surface antigens (including LFA‑1/CD18), triggering complement-dependent lysis and Fc-mediated effector functions (ADCC/phagocytosis) that deplete CD18+ cells.
Polyclonal antibody preparation that depletes and suppresses T lymphocytes to reduce autoimmune marrow destruction.
Polyclonal anti-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and depletes/suppresses T lymphocytes via complement-dependent cytolysis and Fc-mediated clearance, reducing autoreactive T‑cell–mediated marrow destruction.
ALG binds CD45 on T lymphocytes and induces complement-dependent cytolysis and Fc-mediated effector clearance (ADCC/phagocytosis).
Autologous, gene-modified CAR T cells engineered to express an anti-CD30 chimeric antigen receptor and CCR4 to enhance trafficking to the Hodgkin lymphoma microenvironment; CAR engagement of CD30 triggers T-cell activation and cytotoxicity.
Autologous T cells are gene-modified to express an anti‑CD30 chimeric antigen receptor and the chemokine receptor CCR4. CAR binding to CD30 on malignant cells triggers T‑cell activation, cytokine release, proliferation, and targeted cytotoxicity, while CCR4 enhances trafficking to the Hodgkin lymphoma microenvironment via CCL17/CCL22 gradients.
Anti-CD30 CAR T cells bind CD30 on target cells, form an immune synapse, and induce apoptosis via perforin/granzyme release (and Fas–FasL signaling); CCR4 only enhances trafficking.
Polyclonal antibody preparation that depletes and suppresses T lymphocytes to reduce autoimmune marrow destruction.
Polyclonal anti-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and depletes/suppresses T lymphocytes via complement-dependent cytolysis and Fc-mediated clearance, reducing autoreactive T‑cell–mediated marrow destruction.
Polyclonal antibodies bind T‑cell surface antigens (including CD62L) and trigger complement-dependent lysis and Fc receptor–mediated ADCC/phagocytic clearance of the bound T cells.
Autologous HER2 (ERBB2)-targeted CAR T cells engineered with a hypoxia-stimulated CAR expression system to upregulate CAR under low oxygen, enhancing persistence and tumor killing in hypoxic solid tumors.
Autologous T cells engineered to express a HER2-specific chimeric antigen receptor whose expression is driven by a hypoxia-inducible system. In hypoxic tumor microenvironments, CAR expression increases, enabling targeted recognition and killing of HER2-positive tumor cells via T-cell activation, cytokine release, and cytotoxicity; hypoxia-regulated expression enhances T-cell persistence/expansion in solid tumors and may reduce off-tumor activity in normoxia.
HER2-targeted CAR T cells (upregulated in hypoxia) recognize HER2 on tumor cells, form an immune synapse, and kill via T‑cell cytotoxic pathways (perforin/granzyme release and Fas/FasL signaling).